Oral and Poster abstract submissions must be received by 6/17/19 (4:30 pm Central Time).
Please review the Guidelines before submitting an abstract. If you have any questions, please contact firstname.lastname@example.org.
General Presentation Guidelines
Southern Region Burn Conference
The deadline for submission of abstracts is on or before June 17, 2019, 4:30 pm CT. All submissions must be made using the online form.
- Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Acceptance of oral or poster presentation followed by no-show without cause and notification can result in a one year suspension of presenting privileges for the burn center.
- Limitations: Submissions are limited to individuals, educational facilities, and hospitals. Commercial posters or presentations of any type are NOT permitted.
- Notification: Upon approval by the Selections Committee, the presenting author will be notified by email of acceptance. The notification will include the scheduled date and time of the presentation. Notification will be sent on or before August 15, 2019. It is the responsibility of the presenting author to notify additional authors of abstract acceptance.
- Length of oral presentation: Oral presentations will be 15-minute podium presentations with 10 minutes for presentation and 5 minutes for questions from the audience.
- Setup of Posters: SMA will provide a 4-foot TALL by 8-foot WIDE display board. Posters may be installed until 7:00 pm Thursday, December 5 and beginning at 6:30 am on Friday, December 6. Posters MUST be in place by 7:00 am on Friday, December 7 for viewing.
- Presentation of Posters: Posters will be available for viewing Friday, December 6 , 7:00 am through Saturday, December 7 at 10:00 am. You should be prepared to discuss your work during poster rounds on Friday, December 6, 5:00-7:00 pm, during the Welcome Reception.
- Conflicts of Interest / Disclosure: Work submitted for presentation must include acknowledgement of relevant financial relationships with commercial interests (if applicable). Conflicts of Interest must be resolved prior to presentation.
Before you begin, prepare the following information:
Presenting author’s contact details and information
- Name and degree(s)
- Affiliation details: academic title, department, institution, city, state
- Email address
- Full postal address
- Phone number
- Disclosure Information (including off-label discussions)
- Name(s) and degree(s)
- Affiliation details: academic title, department, institution, city, state
- Disclosure Information
Abstract title – limited to 25 words
Abstract text – no limitation on words
Abstracts should clearly state:
- Introduction/Background (knowledge gap)
- 2 -3 learning objectives
Use generic drug names. Trade names must not be used in the title or body of the abstract. If a trade name must be used, include trade names from multiple companies rather than a single company’s trade name.
Questions regarding submissions should be directed to email@example.com or (800) 423-4992.
- Submission of an abstract acknowledges your approval for the abstract to be distributed to attendees at the meeting.
- Accepted abstracts may be published in SMA’s electronic newsletter.
Presenting authors must pay the applicable registration fee. Submission of an abstract constitutes a commitment by the author(s) to present if accepted.
Please do not submit an abstract for consideration if your attendance at the conference is not approved or questionable.
Travel Expenses: Reimbursement is not provided for hotel, air, or other travel expenses related to abstract presentations for the conference.
- Use standard abbreviations.
- Place special or unusual abbreviations in parentheses after the first time the full word appears.
- Do not abbreviate compounds in the title of the abstract.
- Use numerals to indicate numbers, except when beginning sentences.
- Take special care when entering your title as it may be published online exactly as submitted.
- Begin creating your presentation by determining the overall objectives:
- What is the purpose of the presentation?
- What are the main points you want to make?
- Which points are the most important?
- In what order should they be presented?
- If you have to apologize for the appearance of a slide, it should not be shown.
- Project every slide in as large a room as possible to evaluate appearance and readability.
- Always bring your final presentation on a memory stick/flash drive.
- Check your presentation against the following:
- I have used a master slide (preferred) to maintain a similar format/background for all slides within my presentation.
- I have used a sanserif font such as Arial rather than a serif font such as Times New Roman to enhance readability.
- Slide backgrounds are not too dark or too bright.
- Font sizes on slide titles are no smaller than 36 point and bullets are no smaller than 24 point.
- Fonts are not dark over a dark background (for example, red or green on blue background).
- I have avoided using bright orange and reds since they “play tricks” with eyes.
- I have avoided red/green conflicts (20% of your audience has color impaired vision).
- I have used a consistent font on all of my slides such as Arial.
- I do not have more than eight lines per bullet slide (a bullet = a statement on the slide).
- Information is short and to the point.
- I do not have too many slides for the time allotted for my presentation.
- I have labeled all “x” and “y” axes.
- If my axes are labeled, they are the same as the legend.
- I have avoided over 3 lines per graph (limit of 2 is even better and less confusing).
- I have avoided importing scanned graphs/spreadsheets (they do not project well and are very difficult to read).
- I have used the graphing/spreadsheet function of the program instead of scanned graphs.
PowerPoint Slides – Order of Presentation Checklist
- Title Slide
- Lecture title.
- Your name and appropriate academic affiliation(s).
- Disclosure Slide
- List all relevant financial relationships related to the content you are presenting, or state, “I have no relevant financial relationships to disclose”
- Indicate your intent to speak about unapproved/off-label FDA use.
- The purpose of the lecture.
- What the attendee will learn as a result of listening to the lecture.
- Content slides – things to remember:
- Appropriately cite/reference each slide.
- Use generic names vs. trade names for drug therapy whenever possible.
- The number of slides in your lecture should not exceed your allotted time limit.
- Provide a balanced view of therapeutic options or devices (if applicable).
- DO NOT use slides or illustrations that are commercial in origin.
- Request and obtain permission for any material that contains copyright.
- Conclusion Slide
- Summarize key points – relating back to the goals/objectives.
- Resources/Suggested Reading
- Provide additional articles/information to benefit the learner.
ACCME Standard and SMA disclosure and conflict of interest policies
- In accordance with ACCME requirements and SMA policy, abstracts, selected for oral or poster presentation must be free of bias.
- Do not reference any company/product brand names during your presentation. However, institution logos (e.g., non-company/product logos such as universities, non-profit associations and government agencies) are allowed in the body of your presentation.
- SMA requires that educational materials that are part of a CME activity, such as slides, abstracts and handouts, not contain any advertising, trade names or a product group message.
- Disclosures must never include the use of a trade name or a product group message.
- For oral presentations, disclosures must be listed on the second slide of each presentation.
- For poster presentations, disclosures must be listed once at the bottom of the poster.
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Commercial Support and Policies, SMA requires that all individuals who are in a position to control the content of an SMA CME Activity disclose:
- any relevant financial relationships with a commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients occurring over the past twelve months, and;
- any inclusion in a presentation of a commercial product with an unlabeled use or an investigational use not yet approved by the FDA. Any individual who does not comply with this policy will NOT be permitted to participate in SMA’s CME Activity.
Disclosure to Learners - SMA ensures that all attendees/participants of SMA CME activities are informed of all relevant financial relationships (or “no” relationship) disclosed by individuals who are in a position to control the content prior to the beginning of an activity either in print, verbally, or by multimedia display.
Resolution of Conflict of Interest (COI) Policy:
- Live CME, Internet CME, or Enduring Materials – Faculty: Faculty disclosure information, along with the provided content (slides, abstracts, etc.), will be reviewed either internally, by the activity chairperson, or by a reviewer from SMA’s Content Review Committee. If during this process there a COI is identified, SMA Staff will provide direction to correct the conflict. Corrective measures will be documented in the activity file.
- Journal CME review for COI will be handled by the editorial staff. The Southern Medical Journal (SMJ) Editor-in-Chief will receive a copy of the author’s disclosure form and examine the article for (COI) at the time of review for CME approval. If COI is identified, the SMJ Editor-in-Chief will state the required changes necessary to correct the content or may decide to reject the article.
- SMA Leadership, Committees, Journal Editor-in-Chief, etc. – Financial disclosures will be collected on an annual basis. COI will be reviewed in the context of role and current duties to determine the extent of his/her responsibility, and determine if that person’s responsibilities need to be altered or reassigned in order to resolve a COI.
- SMA Staff – Financial disclosures will be collected on an annual basis. COI will be reviewed in the context of each staff member’s role, and by using his/her current job description to determine the extent of his/her responsibilities, and to determine if that person’s responsibilities need to be altered or reassigned to resolve a COI.
Glossary of Terms
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, see www.accme.org.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content regarding products or services of a commercial interest with which he/she has a financial relationship.
Oral Abstract Presentation Guidelines
Southern Region Burn Conference
Refer to General Presentation Guidelines for additional information. The deadline for submission of abstracts is on or before June 17, 2019 4:30 pm CT.
The presenting author will be notified by email of acceptance on or before August 15, 2019. You must respond by August 30 that you accept date/time. Failure to commit by the requested date may result in a replacement presentation.
Questions? Contact Vicki Baugh by email firstname.lastname@example.org or 800-423-4992, ext. 177.
All sessions will take place at the Marriott Rivercenter, San Antonio, TX. Upon arrival, stop by the SMA Registration Desk to pick up your meeting credentials, materials, and a copy of the final meeting program. We strongly recommend taking advantage of early registration on Thursday, 3:00-7:00 pm, to avoid the Friday morning rush when presentations are in progress.
Your presentation should be developed using Microsoft PowerPoint software. The length of the presentation will be 10 minutes for the presentation, plus 5 minutes for questions from the audience for a total of 15 minutes. Bring the final version of your presentation on a flash drive, ready to load, at least 4 hours prior to your start time to be loaded to the meeting room computer.
Audio/Visual Equipment Provided:
Microsoft PowerPoint is the required presentation method. The standard equipment listed below will be provided by SMA:
- Lighted Lectern with Mic / Speaker’s Platform and Laser Pointer
- Computer – Microsoft PowerPoint loaded
- LCD Data Projector
- Projection Screen
Your original abstract will be made available to attendees online prior to and during the meeting.
REGISTRATION AND HOUSING
All presenters must pre-register for the meeting no later than November 11, 2019. Registration and housing information can be found at http://sma.org/burn.